|Table of Contents|

Status and aggregation of metabolic syndrome and its components abnormality in obese patients with malignant tumor

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4414-4419
Research Field:
Publishing date:

Info

Title:
Status and aggregation of metabolic syndrome and its components abnormality in obese patients with malignant tumor
Author(s):
HUANG Weiling; ZHANG Mei; ZHENG Xiaoxia; TONG Luyao; LEI Liyi
Health Management Center,Sichuan Provincial People's Hospital,Affiliated Hospital of University of Electronic Science and Technology of China,Sichuan Chengdu 610072,China.
Keywords:
malignant tumor; metabolic syndrome; cross sectional study; Logistic regression model
PACS:
R730.58
DOI:
10.3969/j.issn.1672-4992.2023.23.022
Abstract:
Objective:To investigate the status and aggregation risk of metabolic syndrome(MetS) and its related components abnormality in obese patients with malignant tumors.Methods:392 physical examinees who had complete physical examination information and had suffered from malignant tumors in the health management center of Sichuan Provincial People's Hospital from January 2020 to June 2022 were taken as the research objects.They were further divided into tumor obesity group and non obesity group.1 658 healthy people without tumor disease history and complete physical examination information were selected as the control group in a ratio of 1∶4 based on gender and age matching.The risk of MetS and its components aggregation in obese tumor patients was analyzed by multivariate Logistic regression model.Results:The prevalence of MetS in tumor obese patients and non tumor obese patients was higher than that in healthy controls(64.3%,57.3% vs 10.1%,χ2=201.829,343.372,P＜0.001),but there was no significant difference in the prevalence of MetS between tumor non obese patients and healthy controls(7.8% vs 10.1%,χ2=1.515,P=0.218).The prevalence of hypertension,hyperglycemia and dyslipidemia in tumor obese patients and non tumor obese patients was higher than those in healthy control group(all P＜0.05).The incidence risk of MetS increased in tumor obese patients and non tumor obese patients ［aOR(95%CI) were 18.320(14.396~23.315) and 11.496(9.033~14.630) respectively］,and the more abnormal components gathered,the greater the incidence risk of MetS ［aOR(95%CI) of abnormal three components and abnormal four components in obese tumor patients were 13.545(10.643~17.237) and 41.431(32.555~52.724) respectively.The aOR(95%CI) of abnormal 3 and 4 components in non tumor obesity group were 8.117(6.378~10.330) and 26.549(20.862~33.787),respectively］.The results of heterogeneity test showed that there was no significant difference in MetS and its component aggregation risk between tumor obese patients and non tumor obese patients(all P＞0.05).Conclusion:The risk of MetS in tumor obese patients and non tumor obese patients was significantly higher than that in non obese and healthy controls.The more abnormal components gathered,the higher the risk of MetS.Therefore,effective weight management should be carried out for tumor obese patients,so as to effectively prevent and control the risk of other chronic diseases of tumor survivors.

References:

[1] SMITH RA,OEFFINGER KC.The importance of cancer screening［J］.Med Clin North Am,2020,104(6):919-938.
[2] 中国临床肿瘤学会指南工作委员会甲状腺癌专家委员.中国临床肿瘤学会(CSCO)持续/复发及转移性分化型甲状腺癌诊疗指南-2019［J］.肿瘤预防与治疗,2019,32(12):1051-1080. Expert Panel on Thyroid Cancer,Guidelines Working Committee of Chinese Society of Clinical Oncology.Guidelines of Chinese society of clinical oncology(csco):persistent/recurrent and metastatic differentiated thyroid cancer-2019［J］.J Cancer Control Treat,2019,32(12):1051-1080.
[3] 中国抗癌协会，国家肿瘤临床医学研究中心(天津医科大学肿瘤医院).中国女性乳腺癌筛查指南［J］.中国肿瘤临床,2019,46(9):430-432. China Anti Cancer Association,National Cancer Clinical Medical Research Center(Cancer Hospital of Tianjin Medical University).Women in China breast cancer screening guidelines［J］.Chinese Journal of Clinical Oncology,2019,46(9):430-432.
[4] HIRODE G,WONG RJ.Trends in the prevalence of metabolic syndrome in the United States,2011-2016［J］.JAMA,2020,323(24):2526-2528.
[5] 郭海健，念馨，梁友芳，等.基于多中心横断面调查的中国人群代谢综合征的流行情况及危险因素［J］.中华疾病控制杂志,2019,23(7):796-801. GUO HJ,NIAN X,LIANG YF,et al.The prevalence and risk factors of metabolic syndrome in Chinese population based on the multi center cross-sectional［J］.Chinese Journal of Disease Control,2019,23(7):796-801.
[6] UZUNLULU M,TELCI CAKLILI O,OGUZ A.Association between metabolic syndrome and cancer［J］.Ann Nutr Metab,2016,68(3):173-179.
[7] KATSIKI N,ANAGNOSTIS P,KOTSA K,et al.Obesity,metabolic syndrome and the risk of microvascular complications in patients with diabetes mellitus［J］.Curr Pharm Des,2019,25(18):2051-2059.
[8] LEISEGANG K,HENKEL R,AGARWAL A.Obesity and metabolic syndrome associated with systemic inflammation and the impact on the male reproductive system［J］.Am J Reprod Immunol,2019,82(5):e13178.
[9] KOKTS-PORIETIS RL,MCNEIL J,NELSON G,et al.Prospective cohort study of metabolic syndrome and endometrial cancer survival［J］.Gynecol Oncol,2020,158(3):727-733.
[10] DAWSON JK,DORFF TB,TODD SCHROEDER E,et al.Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer:a pilot randomized controlled trial［J］.BMC Cancer,2018,18(1):368.
[11] 中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议［J］.中华糖尿病杂志，2004，12(3)：156-161. Collaborative Group of Metabolic Syndrome Research,Diabetes Branch,Chinese Medical Association.Recommendations of diabetes Branch of Chinese Medical Association on metabolic syndrome［J］.Chinese Journal of Diabetes,2004，12(3)：156-161.
[12] PATERNOSTER S,FALASCA M.The intricate relationship between diabetes,obesity and pancreatic cancer［J］.Biochim Biophys Acta Rev Cancer,2020,1873(1):188326.
[13] LAUBY-SECRETAN B,DOSSUS L,MARANT-MICALLEF C,et al.Obesity and cancer［J］.Bull Cancer,2019,106(7-8):635-646.
[14] The Lancet Diabetes Endocrinology.The obesity-cancer link:of increasing concern［J］.Lancet Diabetes Endocrinol,2020,8(3):175.
[15] LEGA IC,LIPSCOMBE LL.Review:diabetes,obesity,and cancer-pathophysiology and clinical implications［J］.Endocr Rev,2020,41(1):bnz014.
[16] 李志学,刘峥,马艳，等.1990-2019年中国人群癌症归因于超重肥胖的疾病负担分析与模型预测［J］.现代肿瘤医学,2023,31(12):2314-2322. LI ZX， LIU Z， MA Y，et al.Cancer burden attributable to excess body weight in China:Trend analysis from 1990 to 2019 and future predictions［J］.Modern Oncology,2023,31(12):2314-2322.
[17] KIM HJ,KIM HS,KIM HR.Characterization of metabolic syndrome risk factors and health-related behaviors in Korean patients with breast cancer by abdominal obesity status［J］.J Nurs Res,2021,28(2):e74.
[18] LITWIN M,KULAGA Z.Obesity,metabolic syndrome,and primary hypertension［J］.Pediatr Nephrol,2021,36(4):825-837.
[19] PIURI G,ZOCCHI M,DELLA PORTA M,et al.Magnesium in obesity,metabolic syndrome,and type 2 diabetes［J］.Nutrients,2021,13(2):320.
[20] KARRA P,WINN M,PAULECK S,et al.Metabolic dysfunction and obesity-related cancer:Beyond obesity and metabolic syndrome［J］.Obesity(Silver Spring),2022,30(7):1323-1334.
[21] 曾慧明，童倩，蔡宇，等.代谢综合征与肺癌恶性程度的相关性探讨［J］.现代肿瘤医学,2022,30(19):3515-3518. ZENG HM,TONG Q,CAI Y,et al.Corrlation between metabolic syndrome and malignant degree of lung cancer［J］.Modern Oncology,2022,30(19):3515-3518.

Memo

Memo:
国家重点研发计划（编号：2017YFC0113901）;四川省科技厅重点研发项目（编号：2019YFS0278）；四川省卫计委课题（编号：20PJ107）
Last Update: 2023-10-31